金军,莫清华,罗元红.培美曲赛联合顺铂复治转移性乳腺癌的临床观察.[J].中南医学科学杂志.,2011,39(4):429-431. |
培美曲赛联合顺铂复治转移性乳腺癌的临床观察 |
Clinical Observation of the Treatment With Pemetrexed and Cisplatin in the Metastatic Breast Cancer |
投稿时间:2011-03-09 |
DOI: |
中文关键词: 培美曲赛 顺铂 转移性乳腺癌 |
英文关键词:pemetrexed cisplatin metastatic breast cancer |
基金项目: |
|
摘要点击次数: 529 |
全文下载次数: 1193 |
中文摘要: |
目的观察培美曲赛联合顺铂治疗转移性乳腺癌的疗效及不良反应,为转移性乳腺癌的治疗提供新的思路和方法。方法8例转移性乳腺癌患者接受培美曲赛联合顺铂方案化疗,培美曲赛500 mg/m2,顺铂75 mg/m2,静脉滴注,每3周重复1次。每两个疗程评价1次。结果8例患者均可评价疗效,其中CR 2例,PR 4例,SD 1例,PD 1例。中位随访时间为6月(2~22月)。7例存活,1例死亡,中位生存期为10月(2~22个月)。治疗中最常见的不良反应是乏力、白细胞减少和消化道反应以及口腔溃疡。结论培美曲赛联合顺铂方案复治转移性乳腺癌能提高患者生存率,其不良反应可以耐受。 |
英文摘要: |
ObjectiveWe observesd the efficacy and adverse reactions of the treatment with pemetrexed and cisplatin in the metastatic breast cancer,in order to provide a new approach.MethodsEight patients with metastatic breast cancer received pemetrexed and cisplatin chemotherapy,the contents of which was pemetrexed 500 mg/m2 intravenous infusion,cisplatin 75 mg/m2 intravenous drip,repeating every 3 weeks.Evaluation of response and adverse reaction were practiced every 2 cycles.ResultAll of the 8 patients could be evalued.The result was CR 2 patients,PR 4 patients,SD 1 patient,PD 1 patient.The media follow-up was 6 months (2~22 monthes).Seven patients survived and one patient died.The media survival time was 10 months (2~22 monthes).The most common adverse reaction was fatigue,white blood cells decrease and the digestive tract reaction,followed by oral ulcers. |
查看全文 查看/发表评论 下载PDF阅读器 |
关闭 |